News Adocia and Lilly's legal tussle intensifies as diabetes deal... It all looked so good in 2011 when Eli Lilly agreed a deal with French biotech Adocia to develop an ultra-rapid insulin, in a deal worth up to $165 million.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face